このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Phase Ⅲ Clinical Trial of an Investigative 24-valent Pneumococcal Polysaccharide Conjugate Vaccine

2026年11月11日 更新者:Reinovax Biologics Co., LTD

Multicenter, Randomized, Double-Blind, Active-Controlled Phase III Trial to Evaluate the Immunogenicity and Safety of a 24-Valent Pneumococcal Conjugate Vaccine (PCV24, RZ700) Following Vaccination in Adults Aged 18 Years and Older

A phase III clinical trial of a 24-valent pneumococcal conjugate vaccine (PCV24) developed by Reinovax Biologics Co., LTD will be conducted in Chinese adults aged 18 years and older.The study's objective is to evaluate the safety and immunogenicity of PCV24. The trial is a multicenter, randomized, double-blind and active-controlled phase III clinical trial.

調査の概要

詳細な説明

A Phase Ⅲ clinical trial of the 24-valent pneumococcal conjugate vaccine (PCV24) developed by Reinovax Biologics Co., LTD will be conducted in Chinese adults aged 18 years and older. The study's objective is to evaluate the safety and immunogenicity of PCV24. The active control vaccine is a 23-valent pneumococcal polysaccharide vaccine (PPSV23) produced by Merck & Co.A total of 1,260 participants will be enrolled, including 756 participants aged 65-74 years, who will be randomized 1:1 to receive one dose of PCV24 or PPSV23, and 84 participants aged 75 years and older, who will be randomized 1:1 to receive one dose of PCV24 or PPSV23. In addition, 420 participants aged 18-64 years will receive one dose of PCV24.

研究の種類

介入

入学 (推定)

1260

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Tao Huang, Bachelor
  • 電話番号:86+15084736658
  • メール:ymlc01@hnedc.com

研究場所

      • Shanghai、中国
        • Shanghai Center for Disease Control and Prevention
        • コンタクト:
    • Hunan
      • Changsha、Hunan、中国
        • Hunan Center for Disease Control and Prevention
        • コンタクト:
    • Yunan
      • Baoshan、Yunan、中国、678000
        • Baoshan Second People's Hospital
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

1)Aged 18 years and older, able to provide valid legal identification; 2)Capable of understanding the clinical trial procedures, voluntarily agreeing to participate, and signing the informed consent form; 3)Willing and able to comply with the requirements of the clinical trial protocol and to attend all scheduled visits; 4) Male participants and female participants of childbearing potential agreeing to use effective contraception within 6 months after vaccination (effective contraceptive measures include: oral contraceptives, injectable or implanted contraceptives, sustained-release topical contraceptives, hormone patches, intrauterine device (IUD), sterilization, abstinence, and condoms (for males)); the rhythm method, coitus interruptus, and emergency contraception are not acceptable contraceptive measures; 5) Axillary temperature ≤37.0°C on the day of enrollment. Exclusion Criteria:

  1. Previous vaccination with any pneumococcal vaccine, or a history of invasive pneumococcal disease caused by Streptococcus pneumoniae within 3 years before enrollment;
  2. History of any severe allergic reaction, such as anaphylactic shock, allergic laryngeal edema, angioneurotic edema, dyspnea, severe urticaria, allergic purpura, or local allergic necrotizing reaction (Arthus reaction); or a history of thrombocytopenic purpura; or known allergy to any component of the investigational vaccine (aluminum phosphate adjuvant, phenol, sodium chloride, succinic acid, polysorbate 80, or water for injection);
  3. Lactating or pregnant women, or women of childbearing potential planning to become pregnant during the study period; women of childbearing potential who have not used effective contraception from the end of their last menstrual cycle until enrollment; or women of childbearing potential with a positive urine pregnancy test at enrollment (sensitivity 25 mIU/mL for β-hCG);
  4. Diagnosed with congenital or acquired immunodeficiency; or other diseases affecting immune function (such as asplenia, functional asplenia, and asplenia or splenectomy due to any cause).
  5. Long-term (continuous ≥14 days) use of immunosuppressants or other immunomodulatory drugs within 3 months before enrollment or planned during the study period [e.g., systemic corticosteroids ≥14 days at a dose of ≥2 mg/kg/day or ≥20 mg/day prednisone or equivalent; topical use is permitted (e.g., ointments, eye drops, inhalers, or nasal sprays), provided the dose does not exceed the recommended dosage in the package insert];
  6. Severe cardiovascular disease, such as myocardial infarction (acute onset within 6 months before signing the informed consent form), cardio-cerebrovascular syndrome, severe arrhythmia, unstable angina, or poorly controlled arrhythmia;
  7. Systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg measured at the screening physical examination on site; for participants with a history of hypertension, enrollment is permitted only if confirmed by inquiry that blood pressure has been stable over the past 3 months and there have been no obvious cardio-cerebrovascular disease-related symptoms in the past 2 weeks;
  8. Receipt of blood or blood-related products, or immunoglobulin within 3 months before enrollment (except hepatitis B immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin);
  9. Vaccination with any other inactivated vaccine within 7 days before vaccination, or with any live attenuated vaccine within 14 days before vaccination;
  10. Acute illness within 3 days before vaccination, or acute exacerbation of a chronic disease, or use of antipyretic/analgesic drugs (excluding medications used to control pre-existing conditions that, in the investigator's judgment, would not affect the evaluation of study results, such as aspirin used for antiplatelet aggregation) or anti-allergic drugs;
  11. Active tuberculosis, active viral hepatitis, or HIV infection; or other active infectious diseases that, in the judgment of the investigator, may affect the safety of vaccination or interfere with the assessment of immunogenicity;
  12. Severe neurological diseases (e.g., uncontrolled epilepsy), or a history of psychiatric disorders affecting normal behavior, or a family history of such diseases with a hereditary tendency;
  13. Diagnosed thrombocytopenia, any coagulation disorder, or receiving anticoagulant therapy, or other conditions contraindicating intramuscular injection;
  14. Severe chronic diseases or chronic diseases in an uncontrolled progressive stage (e.g., uncontrolled diabetes, severe hepatic or renal disease), excluding a history of cured or stable, well-controlled tumors (except malignant tumors);
  15. Use of another investigational or unregistered product (drug or vaccine) within 1 month before enrollment, or current participation in another clinical trial, or planned participation in another clinical trial during the study period;
  16. Any other condition that, in the opinion of the investigator, may interfere with the evaluation of the study.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:防止
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:Experimental group 1

378 participants aged 65-74 years will be randomly assigned to receive Reinovax's PCV24. The route of administration is intramuscular injection into the deltoid muscle of the upper arm. The immunization schedule is 1 dose.

Prevention of pneumococcal infection caused from 24 pneumococcal serotypes (1, 2, 3, 4 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F) using a novel PCV24 prepared with Reinovax's non-toxic dual carrier protein system. Administration of one dose at 0.5 mL

アクティブコンパレータ:Active control group 1

378 participants aged 65-74 years will be randomly assigned to receive PPSV23. The route of administration is intramuscular injection into the lateral deltoid muscle of the upper arm. The immunization schedule is 1 dose.

One dose of PPSV23 (0.5 mL) contains 1、2、3、4、5、6B、7F、8、9N、9V、10A、11A、12F、14、15B、17F、18C、19A、19F、20、22F、23F and 33F polysaccharides.

他の名前:
  • ニューモバックス 23
実験的:Experimental group 2

42 participants aged 75 years and older will be randomly assigned to receive Reinovax's PCV24. The route of administration is intramuscular injection into the deltoid muscle of the upper arm. The immunization schedule is 1 dose.

Prevention of pneumococcal infection caused from 24 pneumococcal serotypes (1, 2, 3, 4 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F) using a novel PCV24 prepared with Reinovax's non-toxic dual carrier protein system. Administration of one dose at 0.5 mL

アクティブコンパレータ:Active control group 2

42 participants aged 75 years and older will be randomly assigned to receive PPSV23. The route of administration is intramuscular injection into the lateral deltoid muscle of the upper arm. The immunization schedule is 1 dose.

One dose of PPSV23 (0.5 mL) contains 1、2、3、4、5、6B、7F、8、9N、9V、10A、11A、12F、14、15B、17F、18C、19A、19F、20、22F、23F and 33F polysaccharides.

他の名前:
  • ニューモバックス 23
実験的:Experimental group 3

420 participants aged 18-64 years will receive Reinovax's PCV24. The route of administration is intramuscular injection into the deltoid muscle of the upper arm. The immunization schedule is 1 dose.

Prevention of pneumococcal infection caused from 24 pneumococcal serotypes (1, 2, 3, 4 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F) using a novel PCV24 prepared with Reinovax's non-toxic dual carrier protein system. Administration of one dose at 0.5 mL

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Functional antibody titers measured by the multiplexed opsonophagocytic assay (MOPA).
時間枠:0~30 days after vaccination

The geometric mean titers (GMTs) of 24 vaccine serotype-specific MOPA antibodies at 0 days and 30 days after vaccination in participants aged 65 years and older, measured by the multiplexed opsonophagocytic assay (MOPA).

0~30 days after vaccination
Proportional participants with the MOPA titer rise of 4-fold or higher
時間枠:0~30 days after vaccination

The percentage of participants aged 65 years and older whose MOPA antibody titers show a 4-fold or greater increase from the pre-immunization baseline at 30 days after vaccination, for each of the 24 vaccine serotypes.

0~30 days after vaccination
Functional antibody titers measured by the multiplexed opsonophagocytic assay (MOPA).
時間枠:0~30 days after vaccination

The geometric mean titers (GMTs) of the 24 vaccine serotype-specific MOPA antibodies at 0 day and 30 days after vaccination in participants aged 18-64 years, measured by the multiplexed opsonophagocytic assay (MOPA).

0~30 days after vaccination
Incidence of adverse events
時間枠:0-30 minutes after vaccination

The incidence of any local and systemic adverse events occurring within 30 minutes after vaccination.

0-30 minutes after vaccination
Incidence of solicited adverse events
時間枠:0-7 days after vaccination

The incidence of solicited adverse events occurring within 7 days after vaccination.

0-7 days after vaccination
Incidence of unsolicited adverse events
時間枠:0-30 days after vaccination

The incidence of unsolicited adverse events occurring within 30 days after vaccination.

0-30 days after vaccination
Incidence of serious adverse events (SAE)
時間枠:0-6 months after vaccination

The incidence of serious adverse events (SAE) occurring within 6 months after vaccination.

0-6 months after vaccination

二次結果の測定

結果測定
メジャーの説明
時間枠
Seropositivity rate as measured using MOPA
時間枠:0~30 days after vaccination

The percentage of participants aged 65 years and older with MOPA antibody titers ≥1:8 for each of the 24 vaccine serotypes, detected by MOPA 30 days after immunization. Unit of measure: percentage of participants.

0~30 days after vaccination
Increase rate of as measured using MOPA
時間枠:0~30 days after vaccination

The percentage of participants aged 65 years and older whose MOPA antibody titer shows a 2-fold or greater increase from the pre-immunization baseline at 30 days after immunization, for each of the 24 vaccine serotypes. Unit of measure: percentage of participants.

0~30 days after vaccination
The geometric mean fold rise (GMFR) of MOPA antibody titers
時間枠:0~30 days after vaccination

The geometric mean fold rise (GMFR) in 24 vaccine serotype-specific MOPA antibody titers from the pre-immunization baseline to 30 days after immunization, and the ratio of GMFR between the vaccine group and the control group, in participants aged 65 years and older.

0~30 days after vaccination
Seropositivity rate of IgG antibodies
時間枠:0~30 days after vaccination

The percentage of participants aged 65 years and older with IgG geometric mean concentration (GMC) ≥0.35 µg/mL for each of the 24 vaccine serotypes, detected by ELISA 30 days after immunization. Unit of measure: percentage of participants.

0~30 days after vaccination
Positive conversion rate of IgG antibodies
時間枠:0~30 days after vaccination

The percentage of participants aged 65 years and older whose IgG antibody concentration shows a 2-fold or greater increase (positive conversion) from the pre-immunization baseline at 30 days after immunization, for each of the 24 vaccine serotypes. Unit of measure: percentage of participants.

0~30 days after vaccination
The IgG geometric mean concentration (GMC) of each serotype
時間枠:0~30 days after vaccination

The geometric mean concentration (GMC) of 24 vaccine serotype-specific IgG antibodies detected by ELISA 30 days after immunization in participants aged 65 years and older.

0~30 days after vaccination
The geometric mean fold rise (GMFR) of IgG antibodies
時間枠:0~30 days after vaccination

The geometric mean fold rise (GMFR) in 24 vaccine serotype-specific IgG antibody concentration from the pre-immunization baseline to 30 days after immunization, and the ratio of GMFR between the vaccine group and the control group, in participants aged 65 years and older.

0~30 days after vaccination
Seropositivity rate of multiplexed opsonophagocytic assay (MOPA) antibodies
時間枠:0~30 days after vaccination

The percentage of participants aged 18-64 years with MOPA antibody titer ≥1:8 for each of the 24 vaccine serotypes, detected by MOPA 30 days after immunization. Unit of measure: percentage of participants.

0~30 days after vaccination
Increase rate of multiplexed opsonophagocytic assay (MOPA) antibodies
時間枠:0~30 days after vaccination

The percentage of participants aged 18-64 years whose MOPA antibody titer shows a 2-fold or greater increase from the pre-immunization baseline (2-fold increase rate), and the percentage whose MOPA antibody titer shows a 4-fold or greater increase from the pre-immunization baseline (4-fold increase rate), at 30 days after immunization for each of the 24 vaccine serotypes. Unit of measure: percentage of participants.

0~30 days after vaccination
The geometric mean fold rise (GMFR) of multiplexed opsonophagocytic assay (MOPA) antibodies
時間枠:0~30 days after vaccination

The geometric mean fold rise (GMFR) in 24 vaccine serotype-specific MOPA antibody titer from the pre-immunization baseline to 30 days after immunization, and the ratio of GMFR between the vaccine group and the control group, in participants aged 18-64 years.

0~30 days after vaccination
Seropositivity rate of IgG antibodies
時間枠:0~30 days after vaccination

The percentage of participants aged 18-64 years with IgG antibody concentration ≥0.35 µg/mL for each of the 24 vaccine serotypes, detected by ELISA 30 days after immunization. Unit of measure: percentage of participants.

0~30 days after vaccination
Positive conversion rate of IgG antibodies
時間枠:0~30 days after vaccination

The percentage of participants aged 18-64 years whose IgG antibody concentration shows a 2-fold or greater increase (positive conversion) from the pre-immunization baseline at 30 days after immunization, for each of the 24 vaccine serotypes. Unit of measure: percentage of participants.

0~30 days after vaccination
The geometric mean concentration (GMC) of specific IgG antibodies
時間枠:0~30 days after vaccination

The geometric mean concentration (GMC) of 24 vaccine serotype-specific IgG antibodies detected by ELISA 30 days after immunization in participants aged 18-64 years.

0~30 days after vaccination
The geometric mean fold rise (GMFR) of specific IgG antibodies
時間枠:0~30 days after vaccination

The geometric mean fold rise (GMFR) in 24 vaccine serotype-specific IgG antibody concentration from the pre-immunization baseline to 30 days after immunization, and the ratio of GMFR between the vaccine group and the control group, in participants aged 18-64 years.

0~30 days after vaccination

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月24日

一次修了 (推定)

2027年10月1日

研究の完了 (推定)

2027年10月1日

試験登録日

最初に提出

2026年9月27日

QC基準を満たした最初の提出物

2026年11月11日

最初の投稿 (実際)

2026年11月17日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月17日

QC基準を満たした最後の更新が送信されました

2026年11月11日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する